RxDoctor Payments Data

Emily Stallard

Acute Care · Gastonia, NCNPI 1205232337

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,073 and has fallen 93.8% since, to $66 in 2024.

$2,604in general payments, 2019–2025

Across 146 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$486
  • AstraZeneca$346
  • AbbVie$167
  • Sanofi$131
  • Lilly USA, LLC$129
  • Mylan Specialty L.p.$115
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,604 in reported general payments places this provider in the 85th percentile of 312 acute care providers in North Carolina.

See all acute care providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,883
Breo ElliptaFluticasone/Vilanterol14$5,688
Albuterol Sulfate HfaAlbuterol Sulfate19$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$486$19,57225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 acute care providers in North Carolina.

Other acute care in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →